| Cameron Family Medicine | |
|
1381 N Wayne St Angola IN 46703-2348 | |
| (260) 665-8222 | |
| (260) 665-8970 |
| Full Name | Cameron Family Medicine |
|---|---|
| Speciality | Clinic/Center |
| Location | 1381 N Wayne St, Angola, Indiana |
| Authorized Official Name and Position | Andrew Aldred (VP/COO) |
| Authorized Official Contact | 2606675330 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Cameron Family Medicine 416 E Maumee St Angola IN 46703-2015 Ph: (260) 665-2141 | Cameron Family Medicine 1381 N Wayne St Angola IN 46703-2348 Ph: (260) 665-8222 |
| NPI Number | 1770521478 |
|---|---|
| Provider Enumeration Date | 06/03/2006 |
| Last Update Date | 04/22/2024 |
| Certification Date | 04/22/2024 |
| Medicare PECOS PAC ID | 9234020835 |
|---|---|
| Medicare Enrollment ID | O20040323001008 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770521478 | NPI | - | NPPES |
| 000000100683 | Other | IN | BUE CROSS BLUE SHIELD |
| 200244480A | Medicaid | IN |
| Provider Name | Jay D Fawver |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1164457404 PECOS PAC ID: 5496701179 Enrollment ID: I20050328000391 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Carlene M Mcclurg |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1235164732 PECOS PAC ID: 0042266678 Enrollment ID: I20050328000424 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Akbar Khan Shinwari |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1033145396 PECOS PAC ID: 3476537671 Enrollment ID: I20050909000969 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Barbara Marie Brown |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1255317996 PECOS PAC ID: 9739103722 Enrollment ID: I20060117001005 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Susan M Frayer |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1598757684 PECOS PAC ID: 5092720391 Enrollment ID: I20060207001008 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Brandon Russell |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1588603708 PECOS PAC ID: 6608844295 Enrollment ID: I20060801000243 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Lynn V Faur |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1326047721 PECOS PAC ID: 2668578204 Enrollment ID: I20070427000549 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Sung O Whang |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1083612139 PECOS PAC ID: 7618065665 Enrollment ID: I20071108000736 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Jessica L Ottenweller Butcher |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1629089453 PECOS PAC ID: 4688764780 Enrollment ID: I20071213000041 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Todd C Rumsey |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1336139062 PECOS PAC ID: 0244220077 Enrollment ID: I20090317000286 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Stefani M Johnston |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1831189554 PECOS PAC ID: 5092872150 Enrollment ID: I20090318000087 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Thomas L Miller |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1326048802 PECOS PAC ID: 5294804928 Enrollment ID: I20090403000276 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Sanjiv G Aggarwal |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1316917511 PECOS PAC ID: 0345397840 Enrollment ID: I20090421000394 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Charles L Maclean |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1821036369 PECOS PAC ID: 9830248889 Enrollment ID: I20090521000237 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Richard A Stoldt |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1104863679 PECOS PAC ID: 4284767849 Enrollment ID: I20100803000355 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Jeanette Deeanne Cochran |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720305782 PECOS PAC ID: 7517090129 Enrollment ID: I20100803001100 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Robin D Moffitt |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1790016301 PECOS PAC ID: 7416080783 Enrollment ID: I20100807000082 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Dean L Mattox |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1801828546 PECOS PAC ID: 4082656764 Enrollment ID: I20100914001279 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Barbara A Matchette |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1144350299 PECOS PAC ID: 8921279936 Enrollment ID: I20110923000365 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Laura M Folds |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1306129283 PECOS PAC ID: 5496920936 Enrollment ID: I20111212000133 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Motaz M Shaher |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1427058825 PECOS PAC ID: 1456333137 Enrollment ID: I20120213000744 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Donna M Lorntz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1144589409 PECOS PAC ID: 7315194297 Enrollment ID: I20120828000772 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Brandy M German |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457623928 PECOS PAC ID: 1355593195 Enrollment ID: I20121130000462 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Diane L Howe |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1770821530 PECOS PAC ID: 1850546862 Enrollment ID: I20130223000068 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Jayne S Sloan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1043650203 PECOS PAC ID: 5294960977 Enrollment ID: I20131105001498 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Taryn D Kaiser |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1740614247 PECOS PAC ID: 5799913323 Enrollment ID: I20140708001076 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Nicole A Deller |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114157641 PECOS PAC ID: 5193947141 Enrollment ID: I20141107000541 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Taylor Hill |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1699171975 PECOS PAC ID: 7416271523 Enrollment ID: I20150121000288 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Tracy D Mangan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1225413487 PECOS PAC ID: 0749594646 Enrollment ID: I20150806009801 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Audra L Lehman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1215301403 PECOS PAC ID: 2860795531 Enrollment ID: I20160129001803 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Patricia S Hall |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1316333867 PECOS PAC ID: 0941518195 Enrollment ID: I20160520001924 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Joey A Dehoff |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1235587361 PECOS PAC ID: 7911292396 Enrollment ID: I20160824001401 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Margaret J Schreiber |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1760537658 PECOS PAC ID: 9234497702 Enrollment ID: I20171212000167 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Melissa L Boyles |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1235176645 PECOS PAC ID: 6800873415 Enrollment ID: I20180410003064 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Chrishawna D Schieber |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255827374 PECOS PAC ID: 4587913868 Enrollment ID: I20180820002548 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Anne E Reitz |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376715185 PECOS PAC ID: 8022293596 Enrollment ID: I20180830003734 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | John A Varner |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1770578338 PECOS PAC ID: 2567409683 Enrollment ID: I20181025002982 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Melchor Mercado |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1750374104 PECOS PAC ID: 4486604329 Enrollment ID: I20190506001222 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Nelson Moy |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1891951406 PECOS PAC ID: 2567682560 Enrollment ID: I20190514000787 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Simon Peter Crass |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1336450766 PECOS PAC ID: 9830484112 Enrollment ID: I20190517001454 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Michael R Rosen |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1639419971 PECOS PAC ID: 8426309386 Enrollment ID: I20190823003179 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Steven A Foley |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1194700179 PECOS PAC ID: 8224932090 Enrollment ID: I20191115000344 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Cheryl Kristine Groth |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1609408004 PECOS PAC ID: 6507280286 Enrollment ID: I20200728002501 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Josiah Wesley Reish |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265047138 PECOS PAC ID: 5698195766 Enrollment ID: I20201012002814 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Gabriela North |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1235743725 PECOS PAC ID: 3476966524 Enrollment ID: I20210108001530 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Christopher J Gasaway |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1134613516 PECOS PAC ID: 4486901048 Enrollment ID: I20210720001383 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Jessica L Baker |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1942968565 PECOS PAC ID: 9436549276 Enrollment ID: I20211209000981 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Trisha D Brown |
|---|---|
| Provider Type | Practitioner - Certified Nurse Midwife (cnm) |
| Provider Identifiers | NPI Number: 1124781943 PECOS PAC ID: 2466844923 Enrollment ID: I20220113002502 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Kelly Bireley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023775707 PECOS PAC ID: 1850787946 Enrollment ID: I20220329000829 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Matthew Sieloff |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1902369952 PECOS PAC ID: 0749515278 Enrollment ID: I20220927000539 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Sherry Jean Handshoe |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1902586829 PECOS PAC ID: 9032571583 Enrollment ID: I20230815002406 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Manasa Musunuri |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1487929816 PECOS PAC ID: 7113147745 Enrollment ID: I20230823000402 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
| Provider Name | Tricia Bowerman |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1447608567 PECOS PAC ID: 7719338540 Enrollment ID: I20240105002770 |
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
News Archive
Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits.
The activity level of a particular gene in lung tumors might identify lung-cancer patients who will likely be helped by a particular chemotherapy regimen given to prevent recurrence after surgery.
Medical researchers, politicians, and policymakers gathered at a Global Health Policy Summit in London Wednesday "to champion innovative solutions to the world's major health problems," Imperial College London reports in an article, which notes the summit, "the first event of its kind, is the result of a partnership between Imperial College London and the Qatar Foundation for education, science and community development" and "will tackle maternal health, primary care, non-infectious diseases and aging societies".
Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.
AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.
› Verified 4 days ago
Kc Learning Center, Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1605 S Wayne St, Angola, IN 46703 Phone: 260-243-6840 | |
Pathway To Clarity, Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 408 N Wayne St, Num 143, Angola, IN 46703 Phone: 260-316-0979 | |
Clarion Call Counseling And Consulting, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 155 S Public Sq, Angola, IN 46703 Phone: 260-665-2972 Fax: 260-665-3026 | |
The Sante' Group, Inc. Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 430 N Wayne St Ste 201, Angola, IN 46703 Phone: 260-668-8797 Fax: 260-665-1620 |